Overview: Biologicals & Immunologicals: Cytotoxic lymphocytes in the treatment and prevention of AIDS

References

• ISFORT RJ, WITTER R, KUNG H: Retrovirus insertion into herpes viruses. Trends Micro biol. (1994) 2:174–177.
   PubMedGoogle Scholar
• RANE DF, DASMAHAPTRA B, SCHWARTZ J: Recent ad-vances in anti-HIV agents. Exp. Opin. Ther. Patents (1994). 4(8): 941–955
   Google Scholar
• BERKE G: The binding and lysis of target T-cells bycytotoxic lymphocytes: molecular and cellular aspects. Ann. Rev. Immunol. (1994) 12: 735–774
   PubMed Web of Science ®Google Scholar
• GOLDBERG AL, ROCK KL: Proteolysis, proteasomes and antigen presentation. Nature (1992). 357:375–379.
   PubMed Web of Science ®Google Scholar
• MOMBURG F, ROELSE J, HOWARD JC, BUTCHER GW,HAMMERLING GJ, NEEFJES JJ: Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Na-ture (1994) 367: 648–651.
   PubMed Web of Science ®Google Scholar
• HAMMOND SA, BOLLINGER RC, TOBERY 1W, SILLICIANO,RF: Transporter-independent processing of HIV-1 enve-lope protein for recognition by CDS T-cells. Nature (1993). 364:158–161.
   PubMed Web of Science ®Google Scholar
• ELVIN J, POITER C, ELLIOTT T, CERUNDOLO V, TOWN-SEND A: A method to quantify binding of unlabeled peptides to class I MUG molecules and detect their allele specificity. j Immunol. Methods (1993) 158: 161–171.
   PubMedGoogle Scholar
• ENGELHARD VH: Structure of peptides associated with class I and class II MHC molecules. Ann. Rev. Immunol.(1994) 12: 181–208.
   PubMed Web of Science ®Google Scholar
• VENET A, WALKER BD: Cytotoxic T-cell epitopes inmV/SW infection. AIDS (1993) 7 Suppl 1: S117–S126.
   Google Scholar
• BERZOFSKY JA: Epitope selection and design of syn-thetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vac-cines. Ann. NY Acad. Sci. (1993). 690:256–264.
   PubMedGoogle Scholar
• SHIRAI M, VACCHIO MS, HODES RJ, BERZOVSKY JA: Preferential V usage by cytotoxic T-cells crossreactive between two epkopes of HIV-1 gp160 and degenerate In class I MHC restriction. J. Immunol. (1993) 151: 2283–2295.
   PubMedGoogle Scholar
• SHIRAI M, PENDLETON CD, AHLERS J, TA10ESHITA T, NEWMAN M, BERZOFSKY JA: Helper-cytotoxic T lympho-cyte (CTL) determinant linkage required for priming of anti-HIV CDS* CTL in vivo with peptide vaccine con-structs. J. Immunol. (1994) 152: 549–556.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, GRAZIOSI C, DEMAREST JF, BUTINI L, MONTRONI M, FOX CH, ORENSTEIN JM, KOTLER DP, FAUCI AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 362: 355–358.
   PubMed Web of Science ®Google Scholar
• EMBRETSON J, ZUPANIC M, RIBAS JL, BURKE A, RACZ P, TENNER-RACZ K, HAASE AT: Massive covert infection of helper T lymphocytes and macrophages by IIW during the incubation period of AIDS. Nature (1993) 362: 359–362.
   PubMed Web of Science ®Google Scholar
• LUZURIAGA K, SULLIVAN JL: IIIV-1 specific CTL in long-term survivors of of vertical infection. J. Cell. Biochem. (1993) Suppl. 17E: 98 (Abstract)
   Google Scholar
• MacKEWICZ CE, ORTEGA HW, LEVY JA: CDfr cell anti-HIV activity correlates with the clinical state of the Infected individual J. Ctn. Invest. (1991). 87: 1462–1466.
   PubMed Web of Science ®Google Scholar
• KULLBERG MC, PEARCE EJ, HIENY SE, SHER A, BERZOFSKYJA: Infection with Scbistosoma mansont alters Thl/Th2 cytokine responses to a non-parasite antigen. J. Immu-nol. (1992) 148: 3264–3270.
   PubMed Web of Science ®Google Scholar
• ACTOR JKD, SHIRAI M, KIJLLBERG MC, DULLER RML, SHERA, BERZOFSKY JA: Helminth infection results in de-creased virus-specific CDS+ cytotoxic T-cell and ml cytokine responses as well as delayed virus clearance. Proc. Natl. Acad. Sci. USA (1993) 90: 948–952.
   PubMedGoogle Scholar
• ZINKERNAGEL RM, HENGARTNER H: T-cell-mediated im-munopathology versus direct cytolysis by virus: impli-cations for HIV and AIDS. Immunol. Today (1994) 15: 262–268.
   PubMedGoogle Scholar
• ALLEN PM, ZINKERNAGEL RM: Immunology: promethean viruses?. Nature (1994) 369: 55–356.
   Google Scholar
• KLENERMAN P, ROWLAND-JONES S, MCADAM S, ED-WARDS J, DAENKE S, LALLOO D, KOPPE B, ROSENBERG W, BOYD D, EDWARDS A, GIANGRANDE P, PHILLIPS RE, MCMICHAEL AJ: Cytotoxic T-cell activity antagonised by naturally occurring IIW-1 gag variants. Nature (1994) 369: 403–407.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, HOUGHTEN R, PUTNEY SD, MARGULIESDH, MOSS B, GERMAIN RN, BERZOFSKY JA: Structural requirements for class I MHC molecule-mediated anti-gen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the human immu-nodeficiency virus envelope protein. J. Exp. Med. (1989) 170: 2023–2035.
   PubMedGoogle Scholar
• PHILLIPS RE, ROWLAND-JONES S, NIXON DF, GOTCH FM,EDWARDS JP, OGUNLESI AO, ELVIN JG, ROTHBARD JA, BANGHAM CRM, RIZZA CR, MCMICHAEL AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition. Nature (1991) 354: 453–459.
   PubMed Web of Science ®Google Scholar
• CEASE KB, BERZOFSKY JA: Towards a vaccine for AIDS: the emergence of immunobiology-based vaccine devel-opment. Ann. Rev. Immunol. (1994) 12: 923–990. Excellent overall review.
   Google Scholar
• RUTHERFORD GW: Long term survival in IIW infection. BMJ(1994) 309: 283–284.
   PubMedGoogle Scholar
• PHILLIPS AN, SABIN CA, ELFORD J, BOFILL M, JANOSSY G, LEE CA: Use of C,D4 lymphocyte count to predict long term survival free of AIDS after HIV infection. BMJ (1994) 309: 309–313.
   PubMed Web of Science ®Google Scholar
• ZHU T, MO H, WANG N, NAM DS, CAO Y, KOUP RA, HODD: Genotypic and phenotypic characterisation of HIV-1 in patients with primary infection. Science (1993) 261: 1179–1181.
   PubMed Web of Science ®Google Scholar
• MARTHAS ML, SUTJIPTO S, MILLER CJ, HIGGINS J, TORTEN J, UNGER RE, MARX PA, PEDERSEN NC, KIYONO H, McGHEE JR: In: Vaccines (1992). BROWN F, CHANOCK RM, GINSBERG HS, LERNER R (Eds.), Cold Spring Harbor Lab Press, Cold Spring Harbor, NY, 117–122.
   Google Scholar
• PUTKONEN P, THORSTENSSON R, ALBERT J, HILD K, NORRBY E, BIBERFELD P, BIBERFELD G: Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian im-munodeficiency virus infection. AIDS (1990) 4:783–789.
   PubMed Web of Science ®Google Scholar
• DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL PK, DESROSIERS RC: ProteCtive effects of a live attenuatedSW vaccine with a deletion in the nef gene. Science (1992) 258: 1938–1941.
   PubMed Web of Science ®Google Scholar
• Protective immunity induced by attenuated retrovirus
   Google Scholar
• FULTZ PN, NARA P, BARRE-SINOUSSI F, CHAPUT A, GREENBERG M L, MUCHMORE E, KIENY M, GERARD M: Vaccine protection of chimpanzees against challenge with HIV- I-infected peripheral blood mononuclear cells. Science (1992). 256: 1687–1689.
   PubMed Web of Science ®Google Scholar
• HU S, ABRAMS K, BARBER GN, MORAN P, ZARLING JM,LANGLOIS AJ, KULLER L, MORTON WR, BENVENISTE RE: Protection of macaques against SW infection by subunit vaccines of SW envelope glycoprotein gp160. Science (1992). 255: 456–459.
   PubMed Web of Science ®Google Scholar
• STOTT EJ, KITCHIN PA, PAGE M, FLANAGAN B, TAFFS LF, CHAN WL, MILLS KHG, SILVERA P, RODGERS A: Anti-cell antibodies in macaques. Nature (1991). 353:393
   PubMed Web of Science ®Google Scholar
• MOSIER DE, GULIZIA RJ, MACISAAC PD, COREY L, GREEN-BERG PD: Resistance to human laununodeflciency virus1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc. Natl. Acad. Sci. USA (1993) 90: 2443–2447.
   PubMed Web of Science ®Google Scholar
• An important approach to defining the immunological correlates of protection
   Google Scholar
• DESROSIERS RC: HIV with multiple gene deletions as alive attenuated vaccine for HIV. AIDS Res. Hum. Retroviruses (1992) 8: 411–421.
   PubMedGoogle Scholar
• FIELDS BN: AIDS: time to turn to basic science. Nature (1994). 569: 95–96.
   Google Scholar
• MacILWAIN C: US puts large-scale AIDS vaccine trials on ice as 'premature'. Nature (1994) 369: 593
   PubMedGoogle Scholar
• NARDELII B, TAM JP: Cellular immune responses in-duced by in vivo priming with a lipid-conjugated mul-thneric antigen peptide. Immunology (1993) 79:355–361.
   PubMedGoogle Scholar
• BOURGAULT I, CHEAT F, TARTAR A, LEVY JP, GMT I.FT JG, VENE'T A: Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus ma-caques of GAG- or NEP-specific cytotoxic T lymphocytes by lipopeptides. j Immunol. (1994) 152: 2530–2537.
   Google Scholar
• LANGLADE DEMOYEN P, NGO GIANG HUONG N, FER-CHAL F, OKSENHENDLER E: Human immunodeficiency virus (IIW) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected pa-tients. J. din. Invest. (1994) 93: 1293–1297,
   PubMedGoogle Scholar
• WALKER BD: The rationale for immunotherapy in HIV-1infection. J. AIDS. (1994). 7 Suppl 1: S6–13.
   Google Scholar